Onderneming Myriad Genetics, Inc.
Aandelen
MYGN
US62855J1043
Medische apparatuur, benodigdheden & distributie
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
18,18 USD | +1,11% | -1,73% | -5,02% |
27/02 | Transcript : Myriad Genetics, Inc., Q4 2023 Earnings Call, Feb 27, 2024 | |
27/02 | Myriad Genetics, Inc. Geeft omzetrichtlijnen voor het eerste kwartaal van 2024 | CI |
Vakgebied
Aantal werknemers: 2 700
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Hereditary Cancers
43,5
%
| 306 | 45,0 % | 328 | 43,5 % | +7,30% |
Prenatal
20,1
%
| 116 | 17,2 % | 151 | 20,1 % | +29,98% |
Pharmacogenomics
18,4
%
| 128 | 18,8 % | 139 | 18,4 % | +8,54% |
Tumor Profiling
18,0
%
| 129 | 19,0 % | 136 | 18,0 % | +5,44% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
89,2
%
| 592 | 87,2 % | 672 | 89,2 % | +13,56% |
Rest of World
10,8
%
| 87 | 12,8 % | 82 | 10,8 % | -6,21% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Paul Diaz
CEO | Chief Executive Officer | 61 | 13-08-20 |
Scott Leffler
DFI | Director of Finance/CFO | 49 | 29/01 |
Dale Muzzey
CTO | Chief Tech/Sci/R&D Officer | 44 | 01-04-14 |
Thomas P. Slavin
CTO | Chief Tech/Sci/R&D Officer | - | 01-03-20 |
Kevin Haas
CTO | Chief Tech/Sci/R&D Officer | 38 | 01-08-18 |
Samraat Raha
COO | Chief Operating Officer | 52 | 11/12 |
Glenn Farrell
IRO | Public Communications Contact | - | 19-12-22 |
Matthew Scalo
IRC | Investor Relations Contact | - | 01-08-22 |
John Oberg
PRN | Corporate Officer/Principal | - | 03-01-23 |
Natalie Munk
AUD | Comptroller/Controller/Auditor | 43 | 01-07-20 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
S. Phanstiel
CHM | Chairman | 65 | 16-09-09 |
Paul Bisaro
BRD | Director/Board Member | 63 | 31-10-22 |
Dan Spiegelman
BRD | Director/Board Member | 65 | 27-05-20 |
Paul Diaz
CEO | Chief Executive Officer | 61 | 13-08-20 |
Lee Newcomer
BRD | Director/Board Member | 71 | 25-09-19 |
Colleen Reitan
BRD | Director/Board Member | 64 | 25-09-19 |
Heiner Dreismann
BRD | Director/Board Member | 69 | 10-06-10 |
Director/Board Member | 50 | 21-07-20 | |
Rashmi Kumar
BRD | Director/Board Member | 53 | 10-09-20 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 90 478 255 | 88 355 484 ( 97,65 %) | 0 | 97,65 % |
Bedrijfsgegevens
Sector
Verkoop per activiteit
Verkoop per regio
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-5,02% | 1,64 mld. | |
+0,89% | 12,8 mld. | |
-10,29% | 7,61 mld. | |
+1,78% | 5,41 mld. | |
-1,16% | 4,51 mld. | |
+5,74% | 4,49 mld. | |
-50,70% | 3,29 mld. | |
+12,21% | 2,73 mld. | |
-16,13% | 2,02 mld. | |
-11,50% | 1,73 mld. |
- Beurs
- Aandelen
- Koers MYGN
- Onderneming Myriad Genetics, Inc.